Pipeline

Addressing life-threatening, difficult-to-treat solid tumors

A2 Bio’s Pipeline

Our rich pipeline includes four pre-clinical programs with different clinically validated solid tumor targets. Tmod™ technology is modular, flexible and compatible with many types of immune cells, as well as manufacturing platforms. A2 Bio is focusing on the use of T cells for our initial pipeline.

Our pipeline

Our pipeline

AUTOLOGOUS

PROGRAM

A2B530

ACTIVATOR

CEA

BLOCKER

HLA-A*02

INDICATION

Colorectal, Lung, and Pancreatic Cancers

Target IND Submission

H2 2022

Commercial Rights

Discovery

IND-Enabling

Phase1

Phase2

AUTOLOGOUS

PROGRAM

A2B694

ACTIVATOR

MSLN

BLOCKER

HLA-A*02

INDICATION

Ovarian, Mesothelioma, Colorectal, Lung and Pancreatic Cancers

Target IND Submission

H1 2023

Commercial Rights

Discovery

IND-Enabling

Phase1

Phase2

ALLOGENEIC

PROGRAM

Undisclosed

ACTIVATOR

Undisclosed

BLOCKER

Undisclosed

INDICATION

Undisclosed

Target IND Submission

H1 2024

Commercial Rights

A2 Bio Investors Merck logo

Discovery

IND-Enabling

Phase1

Phase2

ALLOGENEIC

PROGRAM

Undisclosed

ACTIVATOR

Undisclosed

BLOCKER

Undisclosed

INDICATION

Undisclosed

Target IND Submission

H2 2024

Commercial Rights

Discovery

IND-Enabling

Phase1

Phase2

Programs

Our two lead programs are autologous, followed by two allogeneic candidates. The Tmod™ platform is modular, enabling vast pipeline expansion opportunities. Additional therapies can be created by varying activator and blocker combinations.

Watch how Tmod™ T cells selectively kill tumor cells while sparing normal cells

A2 Bio’s candidate has been validated by robust pre-clinical in vitro and in vivo studies. Tmod™ CEA-targeted CAR T cells, A2B530, can seek CEA expressing tumors, then activate, proliferate and eliminate the tumors while protecting against activity on normal tissues.

Clinical trials

BASECAMP-1

BASECAMP-1 is a pre-screening protocol to identify potential eligible patients for our future trials. The objective of BASECAMP-1 is to use next-generation sequencing to collect information on solid tumor loss of human leukocyte antigen (HLA) and perform leukapheresis to collect and store eligible participants’ own T cells for future use to potentially make a CAR T cell therapy for their disease treatment. For more information and participating cell therapy sites of excellence, visit BASECAMP-1 (NCT04981119).